Brazil Makes Drug Prices Transparent To Strengthen Hand In Pricing Talks
Brazil wants to drive competition and lower drug prices by obliging health authorities to publish the prices paid for all drugs bought by the national health system. A voluntary system has already helped save $1bn and cut the price of Gilead’s Sovaldi by around 30%.
You may also be interested in...
Brazil could soon be manufacturing its own generic version of Gilead’s Sovaldi if opposition to the company’s patent application is upheld by the patent office.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.